Literature DB >> 619124

Effects of d-amphetamine, monomethoxyamphetamines and hallucinogens on schedule-controlled behavior.

R A Harris, D Snell, H H Loh.   

Abstract

The effects of 16 drugs were studied in rats responding under fixed-ratio (FR 30) and fixed-interval (FI 2 minute) schedules of food presentation. The drugs tested included lysergic acid diethylamide (LSD), dimethyltryptamine, mescaline, d-amphetamine and 12 methoxylated amphetamines. All of the drugs decreased the average rates of responding under both schedules, but their potencies varied widely. For example, with LSD, the most potent drug tested, doses of 0.1 to 0.3 mg/kg were sufficient to reduce responding while with dimethyltryptamine and mescaline, doses of 10 to 30 mg/kg were required to clearly reduce responding. For the 12 drugs which are known to produce hallucinogenic effects, their potencies in reducing responding were positively correlated with their reported potencies in producing these subjective effects in humans. Although all of the drugs decreased the average rates of responding, alterations in the patterns of responding under the FR and FI schedules varied among the drugs. Analysis of responding under the FI schedule indicated that d-amphetamine, m-methoxyamphetamine, p-methoxyamphetamine, LSD and 3,4-methylenedioxyamphetamine generally increased the low rates of responding occurring at the beginning of each interval and decreased the high rates of responding occurring later in each interval (rate-dependent effects). The other drugs generally decreased responding throughout the interval. These results are discussed in terms of the known neurochemical effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 619124

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Effects of stimulants, anorectics, and related drugs on schedule-controlled behavior.

Authors:  A D Harris; D Snell; H H Loh
Journal:  Psychopharmacology (Berl)       Date:  1978-01-31       Impact factor: 4.530

2.  Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists.

Authors:  Patrick A Randall; Eric J Nunes; Simone L Janniere; Colin M Stopper; Andrew M Farrar; Thomas N Sager; Younis Baqi; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2011-02-24       Impact factor: 4.530

3.  Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence.

Authors:  Chen Zhang; Yiru Fang; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2010-12-29       Impact factor: 3.533

4.  Effects of methamphetamine and scopolamine on variability of response location.

Authors:  J M Moerschbaecher; D M Thompson; J R Thomas
Journal:  J Exp Anal Behav       Date:  1979-09       Impact factor: 2.468

5.  Cocaine, d-amphetamine, and pentobarbital effects on responding maintained by food or cocaine in rhesus monkeys.

Authors:  S Herling; D A Downs; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1979-09       Impact factor: 4.530

6.  Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose.

Authors:  Tomás Pálenícek; Marie Balíková; Vera Bubeníková-Valesová; Jirí Horácek
Journal:  Psychopharmacology (Berl)       Date:  2007-10-07       Impact factor: 4.530

7.  Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon.

Authors:  R J Lamb; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat.

Authors:  Antonio Ferragud; Clara Velázquez-Sánchez; Vicente Hernández-Rabaza; Amparo Nácher; Virginia Merino; Miguel Cardá; Juan Murga; Juan J Canales
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.